Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

An HK2 Antisense Oligonucleotide Induces Synthetic Lethality in HK1-HK2+ Multiple Myeloma.

Xu S, Zhou T, Doh HM, Trinh KR, Catapang A, Lee JT, Braas D, Bayley NA, Yamada RE, Vasuthasawat A, Sasine JP, Timmerman JM, Larson SM, Kim Y, MacLeod AR, Morrison SL, Herschman HR.

Cancer Res. 2019 May 15;79(10):2748-2760. doi: 10.1158/0008-5472.CAN-18-2799. Epub 2019 Mar 18.

2.

Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study.

Ansell SM, Minnema MC, Johnson P, Timmerman JM, Armand P, Shipp MA, Rodig SJ, Ligon AH, Roemer MGM, Reddy N, Cohen JB, Assouline S, Poon M, Sharma M, Kato K, Samakoglu S, Sumbul A, Grigg A.

J Clin Oncol. 2019 Feb 20;37(6):481-489. doi: 10.1200/JCO.18.00766. Epub 2019 Jan 8.

3.

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.

Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, Lin Y, Braunschweig I, Hill BT, Timmerman JM, Deol A, Reagan PM, Stiff P, Flinn IW, Farooq U, Goy A, McSweeney PA, Munoz J, Siddiqi T, Chavez JC, Herrera AF, Bartlett NL, Wiezorek JS, Navale L, Xue A, Jiang Y, Bot A, Rossi JM, Kim JJ, Go WY, Neelapu SS.

Lancet Oncol. 2019 Jan;20(1):31-42. doi: 10.1016/S1470-2045(18)30864-7. Epub 2018 Dec 2.

4.

18F-labeled anti-human CD20 cys-diabody for same-day immunoPET in a model of aggressive B cell lymphoma in human CD20 transgenic mice.

Zettlitz KA, Tavaré R, Tsai WK, Yamada RE, Ha NS, Collins J, van Dam RM, Timmerman JM, Wu AM.

Eur J Nucl Med Mol Imaging. 2019 Feb;46(2):489-500. doi: 10.1007/s00259-018-4214-x. Epub 2018 Nov 19.

PMID:
30456475
5.

Activity of Anti-CD19 Chimeric Antigen Receptor T Cells Against B Cell Lymphoma Is Enhanced by Antibody-Targeted Interferon-Alpha.

Young PA, Yamada RE, Trinh KR, Vasuthasawat A, De Oliveira S, Yamada DH, Morrison SL, Timmerman JM.

J Interferon Cytokine Res. 2018 Jun;38(6):239-254. doi: 10.1089/jir.2018.0030.

6.

Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial.

Armand P, Engert A, Younes A, Fanale M, Santoro A, Zinzani PL, Timmerman JM, Collins GP, Ramchandren R, Cohen JB, De Boer JP, Kuruvilla J, Savage KJ, Trneny M, Shipp MA, Kato K, Sumbul A, Farsaci B, Ansell SM.

J Clin Oncol. 2018 May 10;36(14):1428-1439. doi: 10.1200/JCO.2017.76.0793. Epub 2018 Mar 27. Erratum in: J Clin Oncol. 2018 Sep 10;36(26):2748.

7.

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.

Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Timmerman JM, Stiff PJ, Friedberg JW, Flinn IW, Goy A, Hill BT, Smith MR, Deol A, Farooq U, McSweeney P, Munoz J, Avivi I, Castro JE, Westin JR, Chavez JC, Ghobadi A, Komanduri KV, Levy R, Jacobsen ED, Witzig TE, Reagan P, Bot A, Rossi J, Navale L, Jiang Y, Aycock J, Elias M, Chang D, Wiezorek J, Go WY.

N Engl J Med. 2017 Dec 28;377(26):2531-2544. doi: 10.1056/NEJMoa1707447. Epub 2017 Dec 10.

8.

ImmunoPET of Malignant and Normal B Cells with 89Zr- and 124I-Labeled Obinutuzumab Antibody Fragments Reveals Differential CD20 Internalization In Vivo.

Zettlitz KA, Tavaré R, Knowles SM, Steward KK, Timmerman JM, Wu AM.

Clin Cancer Res. 2017 Dec 1;23(23):7242-7252. doi: 10.1158/1078-0432.CCR-17-0855. Epub 2017 Sep 19.

9.

Anti-CD20-interleukin-21 fusokine targets malignant B cells via direct apoptosis and NK-cell-dependent cytotoxicity.

Bhatt S, Parvin S, Zhang Y, Cho HM, Kunkalla K, Vega F, Timmerman JM, Shin SU, Rosenblatt JD, Lossos IS.

Blood. 2017 Apr 20;129(16):2246-2256. doi: 10.1182/blood-2016-09-738211. Epub 2017 Jan 30.

PMID:
28137826
10.

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia.

Boyiadzis M, Bishop MR, Abonour R, Anderson KC, Ansell SM, Avigan D, Barbarotta L, Barrett AJ, Van Besien K, Bergsagel PL, Borrello I, Brody J, Brufsky J, Cairo M, Chari A, Cohen A, Cortes J, Forman SJ, Friedberg JW, Fuchs EJ, Gore SD, Jagannath S, Kahl BS, Kline J, Kochenderfer JN, Kwak LW, Levy R, de Lima M, Litzow MR, Mahindra A, Miller J, Munshi NC, Orlowski RZ, Pagel JM, Porter DL, Russell SJ, Schwartz K, Shipp MA, Siegel D, Stone RM, Tallman MS, Timmerman JM, Van Rhee F, Waller EK, Welsh A, Werner M, Wiernik PH, Dhodapkar MV.

J Immunother Cancer. 2016 Dec 20;4:90. doi: 10.1186/s40425-016-0188-z. eCollection 2016.

11.

Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial.

Younes A, Santoro A, Shipp M, Zinzani PL, Timmerman JM, Ansell S, Armand P, Fanale M, Ratanatharathorn V, Kuruvilla J, Cohen JB, Collins G, Savage KJ, Trneny M, Kato K, Farsaci B, Parker SM, Rodig S, Roemer MG, Ligon AH, Engert A.

Lancet Oncol. 2016 Sep;17(9):1283-94. doi: 10.1016/S1470-2045(16)30167-X. Epub 2016 Jul 20.

12.

Targeted immunotherapy using anti-CD138-interferon α fusion proteins and bortezomib results in synergistic protection against multiple myeloma.

Vasuthasawat A, Yoo EM, Trinh KR, Lichtenstein A, Timmerman JM, Morrison SL.

MAbs. 2016 Oct;8(7):1386-1397. Epub 2016 Jun 30.

13.

Suppression of Fcγ-receptor-mediated antibody effector function during persistent viral infection.

Yamada DH, Elsaesser H, Lux A, Timmerman JM, Morrison SL, de la Torre JC, Nimmerjahn F, Brooks DG.

Immunity. 2015 Feb 17;42(2):379-390. doi: 10.1016/j.immuni.2015.01.005. Epub 2015 Feb 10.

14.

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.

Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry D, Freeman GJ, Rodig SJ, Chapuy B, Ligon AH, Zhu L, Grosso JF, Kim SY, Timmerman JM, Shipp MA, Armand P.

N Engl J Med. 2015 Jan 22;372(4):311-9. doi: 10.1056/NEJMoa1411087. Epub 2014 Dec 6.

15.

Antibody-cytokine fusion proteins for treatment of cancer: engineering cytokines for improved efficacy and safety.

Young PA, Morrison SL, Timmerman JM.

Semin Oncol. 2014 Oct;41(5):623-36. doi: 10.1053/j.seminoncol.2014.08.002. Epub 2014 Aug 12. Review.

16.

Active idiotypic vaccination versus control immunotherapy for follicular lymphoma.

Levy R, Ganjoo KN, Leonard JP, Vose JM, Flinn IW, Ambinder RF, Connors JM, Berinstein NL, Belch AR, Bartlett NL, Nichols C, Emmanouilides CE, Timmerman JM, Gregory SA, Link BK, Inwards DJ, Freedman AS, Matous JV, Robertson MJ, Kunkel LA, Ingolia DE, Gentles AJ, Liu CL, Tibshirani R, Alizadeh AA, Denney DW Jr.

J Clin Oncol. 2014 Jun 10;32(17):1797-803. doi: 10.1200/JCO.2012.43.9273. Epub 2014 May 5.

17.

Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial.

Armand P, Nagler A, Weller EA, Devine SM, Avigan DE, Chen YB, Kaminski MS, Holland HK, Winter JN, Mason JR, Fay JW, Rizzieri DA, Hosing CM, Ball ED, Uberti JP, Lazarus HM, Mapara MY, Gregory SA, Timmerman JM, Andorsky D, Or R, Waller EK, Rotem-Yehudar R, Gordon LI.

J Clin Oncol. 2013 Nov 20;31(33):4199-206. doi: 10.1200/JCO.2012.48.3685. Epub 2013 Oct 14.

18.

Anti-CD20-interferon-β fusion protein therapy of murine B-cell lymphomas.

Trinh KR, Vasuthasawat A, Steward KK, Yamada RE, Timmerman JM, Morrison SL.

J Immunother. 2013 Jun;36(5):305-18. doi: 10.1097/CJI.0b013e3182993eb9.

19.

A phase I dose-finding trial of recombinant interleukin-21 and rituximab in relapsed and refractory low grade B-cell lymphoproliferative disorders.

Timmerman JM, Byrd JC, Andorsky DJ, Yamada RE, Kramer J, Muthusamy N, Hunder N, Pagel JM.

Clin Cancer Res. 2012 Oct 15;18(20):5752-60. doi: 10.1158/1078-0432.CCR-12-0456. Epub 2012 Aug 14.

20.

Combination of cyclophosphamide, rituximab, and intratumoral CpG oligodeoxynucleotide successfully eradicates established B cell lymphoma.

Betting DJ, Hurvitz SA, Steward KK, Yamada RE, Kafi K, van Rooijen N, Timmerman JM.

J Immunother. 2012 Sep;35(7):534-43. doi: 10.1097/CJI.0b013e318261e679.

PMID:
22892450
21.

Analysis of Fcγ receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients.

Hurvitz SA, Betting DJ, Stern HM, Quinaux E, Stinson J, Seshagiri S, Zhao Y, Buyse M, Mackey J, Driga A, Damaraju S, Sliwkowski MX, Robert NJ, Valero V, Crown J, Falkson C, Brufsky A, Pienkowski T, Eiermann W, Martin M, Bee V, Marathe O, Slamon DJ, Timmerman JM.

Clin Cancer Res. 2012 Jun 15;18(12):3478-86. doi: 10.1158/1078-0432.CCR-11-2294. Epub 2012 Apr 13.

22.

Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells.

Andorsky DJ, Yamada RE, Said J, Pinkus GS, Betting DJ, Timmerman JM.

Clin Cancer Res. 2011 Jul 1;17(13):4232-44. doi: 10.1158/1078-0432.CCR-10-2660. Epub 2011 May 3.

23.

Targeted delivery of interferon-alpha via fusion to anti-CD20 results in potent antitumor activity against B-cell lymphoma.

Xuan C, Steward KK, Timmerman JM, Morrison SL.

Blood. 2010 Apr 8;115(14):2864-71. doi: 10.1182/blood-2009-10-250555. Epub 2010 Feb 4.

24.

ImmunoPET imaging of B-cell lymphoma using 124I-anti-CD20 scFv dimers (diabodies).

Olafsen T, Sirk SJ, Betting DJ, Kenanova VE, Bauer KB, Ladno W, Raubitschek AA, Timmerman JM, Wu AM.

Protein Eng Des Sel. 2010 Apr;23(4):243-9. doi: 10.1093/protein/gzp081. Epub 2010 Jan 6.

25.

Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma.

Ansell SM, Hurvitz SA, Koenig PA, LaPlant BR, Kabat BF, Fernando D, Habermann TM, Inwards DJ, Verma M, Yamada R, Erlichman C, Lowy I, Timmerman JM.

Clin Cancer Res. 2009 Oct 15;15(20):6446-53. doi: 10.1158/1078-0432.CCR-09-1339. Epub 2009 Oct 6.

26.

Recombinant anti-CD20 antibody fragments for small-animal PET imaging of B-cell lymphomas.

Olafsen T, Betting D, Kenanova VE, Salazar FB, Clarke P, Said J, Raubitschek AA, Timmerman JM, Wu AM.

J Nucl Med. 2009 Sep;50(9):1500-8. doi: 10.2967/jnumed.108.060426. Epub 2009 Aug 18.

27.

Intratumoral but not systemic delivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B cell lymphoma.

Betting DJ, Yamada RE, Kafi K, Said J, van Rooijen N, Timmerman JM.

J Immunother. 2009 Jul-Aug;32(6):622-31. doi: 10.1097/CJI.0b013e3181ab23f1.

PMID:
19483647
28.

Carrier protein conjugate vaccines: the "missing link" to improved antibody and CTL responses?

Timmerman JM.

Hum Vaccin. 2009 Mar;5(3):181-3. Epub 2009 Mar 24. Review.

PMID:
19246995
29.

Tumor-specific recombinant idiotype immunisation after chemotherapy as initial treatment for follicular non-Hodgkin lymphoma.

Timmerman JM, Vose JM, Czerwinski DK, Weng WK, Ingolia D, Mayo M, Denney DW, Levy R.

Leuk Lymphoma. 2009 Jan;50(1):37-46. doi: 10.1080/10428190802563355.

30.

Maleimide conjugation markedly enhances the immunogenicity of both human and murine idiotype-KLH vaccines.

Kafi K, Betting DJ, Yamada RE, Bacica M, Steward KK, Timmerman JM.

Mol Immunol. 2009 Jan;46(3):448-56. doi: 10.1016/j.molimm.2008.10.020. Epub 2008 Nov 28.

31.

Enhanced immune stimulation by a therapeutic lymphoma tumor antigen vaccine produced in insect cells involves mannose receptor targeting to antigen presenting cells.

Betting DJ, Mu XY, Kafi K, McDonnel D, Rosas F, Gold DP, Timmerman JM.

Vaccine. 2009 Jan 7;27(2):250-9. doi: 10.1016/j.vaccine.2008.10.055. Epub 2008 Nov 8.

32.

Sulfhydryl-based tumor antigen-carrier protein conjugates stimulate superior antitumor immunity against B cell lymphomas.

Betting DJ, Kafi K, Abdollahi-Fard A, Hurvitz SA, Timmerman JM.

J Immunol. 2008 Sep 15;181(6):4131-40.

33.

Interleukin-21: biology and application to cancer therapy.

Andorsky DJ, Timmerman JM.

Expert Opin Biol Ther. 2008 Sep;8(9):1295-307. doi: 10.1517/14712598.8.9.1295 . Review.

PMID:
18694350
34.

Dendritic cells loaded with apoptotic antibody-coated tumor cells provide protective immunity against B-cell lymphoma in vivo.

Franki SN, Steward KK, Betting DJ, Kafi K, Yamada RE, Timmerman JM.

Blood. 2008 Feb 1;111(3):1504-11. Epub 2007 Nov 9.

35.

Vaccine therapies for non-Hodgkin's lymphomas.

Montross S, Timmerman JM.

Cancer Treat Res. 2006;131:283-315. Review. No abstract available.

PMID:
16704173
36.

Current status of therapeutic vaccines for non-Hodgkin's lymphoma.

Hurvitz SA, Timmerman JM.

Curr Opin Oncol. 2005 Sep;17(5):432-40. Review.

PMID:
16093791
37.

Recombinant, tumour-derived idiotype vaccination for indolent B cell non-Hodgkin's lymphomas: a focus on FavId.

Hurvitz SA, Timmerman JM.

Expert Opin Biol Ther. 2005 Jun;5(6):841-52.

PMID:
15952914
38.

Cancer vaccines: pessimism in check.

Timmerman JM, Levy R.

Nat Med. 2004 Dec;10(12):1279; author reply 1279-80. No abstract available.

PMID:
15682512
39.

C-reactive protein does not relax vascular smooth muscle: effects mediated by sodium azide in commercially available preparations.

Swafford AN Jr, Bratz IN, Knudson JD, Rogers PA, Timmerman JM, Tune JD, Dick GM.

Am J Physiol Heart Circ Physiol. 2005 Apr;288(4):H1786-95. Epub 2004 Nov 24.

40.

Therapeutic idiotype vaccines for non-Hodgkin's lymphoma.

Timmerman JM.

Adv Pharmacol. 2004;51:271-93. Review. No abstract available.

PMID:
15464914
41.

Extending the utility of gene profiling data by bridging microarray platforms.

Ferl GZ, Timmerman JM, Witte ON.

Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):10585-7. Epub 2003 Sep 8. No abstract available.

42.

Immunotherapy for lymphomas.

Timmerman JM.

Int J Hematol. 2003 Jun;77(5):444-55. Review.

PMID:
12841382
43.

Antitumor immunity after vaccination with B lymphoma cells overexpressing a triad of costimulatory molecules.

Briones J, Timmerman JM, Panicalli DL, Levy R.

J Natl Cancer Inst. 2003 Apr 2;95(7):548-55.

PMID:
12671023
44.

Determinant spreading and tumor responses after peptide-based cancer immunotherapy.

Ribas A, Timmerman JM, Butterfield LH, Economou JS.

Trends Immunol. 2003 Feb;24(2):58-61. Review.

PMID:
12547500
45.

Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma.

Timmerman JM, Singh G, Hermanson G, Hobart P, Czerwinski DK, Taidi B, Rajapaksa R, Caspar CB, Van Beckhoven A, Levy R.

Cancer Res. 2002 Oct 15;62(20):5845-52.

46.

Vaccine therapies for non-Hodgkin's lymphoma.

Timmerman JM.

Curr Treat Options Oncol. 2002 Aug;3(4):307-15. Review.

PMID:
12074767
47.

Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients.

Timmerman JM, Czerwinski DK, Davis TA, Hsu FJ, Benike C, Hao ZM, Taidi B, Rajapaksa R, Caspar CB, Okada CY, van Beckhoven A, Liles TM, Engleman EG, Levy R.

Blood. 2002 Mar 1;99(5):1517-26.

PMID:
11861263
48.

BLyS and BLyS receptor expression in non-Hodgkin's lymphoma.

Briones J, Timmerman JM, Hilbert DM, Levy R.

Exp Hematol. 2002 Feb;30(2):135-41.

PMID:
11823048
49.

The history of the development of vaccines for the treatment of lymphoma.

Timmerman JM, Levy R.

Clin Lymphoma. 2000 Sep;1(2):129-39; discussion 140.

PMID:
11707821
50.

Idiotype-encoding recombinant adenoviruses provide protective immunity against murine B-cell lymphomas.

Timmerman JM, Caspar CB, Lambert SL, Syrengelas AD, Levy R.

Blood. 2001 Mar 1;97(5):1370-7.

PMID:
11222382

Supplemental Content

Loading ...
Support Center